会议报道

订阅

MedSci主页 / 所有栏目 / 会议报道

比较氟维司群与阿那曲唑治疗晚期乳腺癌的多中心、随机、双盲、双模拟、安慰剂对照的Ⅲ期临床试验

2010-09-19 MedSci原创 MedSci原创

乳腺癌徐兵河研究
关注

　　报告者：中国医学科学院肿瘤医院徐兵河 　　时间：9 月17 日10:00～10:20 　　地点：16 区1 层大宴会厅 　　氟维司群是一种雌激素受体（ER）“灭活剂”，本研究比较了氟维司群和芳香化酶抑制剂阿那曲唑对曾接受抗激素治疗失败的中国女性晚期乳腺癌患者的疗效和安全性。  　　234例患者随机分入氟维司群250 mg/月（121例）或阿那曲唑1 m

　　报告者：中国医学科学院肿瘤医院徐兵河

　　时间：9 月17 日10:00～10:20

　　地点：16 区1 层大宴会厅

　　氟维司群是一种雌激素受体（ER）“灭活剂”，本研究比较了氟维司群和芳香化酶抑制剂阿那曲唑对曾接受抗激素治疗失败的中国女性晚期乳腺癌患者的疗效和安全性。 

　　234例患者随机分入氟维司群250 mg/月（121例）或阿那曲唑1 mg/日（113例）治疗组。主要研究终点为TTP，次要研究终点包括ORR、缓解期（DoR）、临床受益率（CBR）以及至治疗失败时间（TTF）。 

　　本研究结果表明，氟维司群250 mg和阿那曲唑对曾接受内分泌治疗进展或复发的中国绝经后晚期乳腺癌妇女具有相似的疗效和很好的耐受性。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-12-23 luoxiaog

    #多中心#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2011-06-27 amyloid

    #对照#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 wleon8895

    #安慰剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 jiangfeng5068

    #阿那曲唑#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 dinorsor527

    #Ⅲ期临床#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 xlxchina

    #双盲#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1903883, encodeId=5619190388303, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Dec 23 04:51:00 CST 2010, time=2010-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775243, encodeId=56301e7524393, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon Jun 27 11:51:00 CST 2011, time=2011-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1304307, encodeId=3705130430ead, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45808, encryptionId=81724580886, topicName=安慰剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cce318, createdName=wleon8895, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412257, encodeId=d2e5141225e03, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495842, encodeId=01b61495842b2, content=<a href='/topic/show?id=351f956559' target=_blank style='color:#2F92EE;'>#Ⅲ期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9565, encryptionId=351f956559, topicName=Ⅲ期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe6c9221933, createdName=dinorsor527, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573039, encodeId=773d15e303982, content=<a href='/topic/show?id=fef43e52220' target=_blank style='color:#2F92EE;'>#双盲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37522, encryptionId=fef43e52220, topicName=双盲)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db3115807173, createdName=xlxchina, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585544, encodeId=3b81158554439, content=<a href='/topic/show?id=04514581178' target=_blank style='color:#2F92EE;'>#安慰剂对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45811, encryptionId=04514581178, topicName=安慰剂对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b4217235139, createdName=guoyibin, createdTime=Tue Sep 21 10:51:00 CST 2010, time=2010-09-21, status=1, ipAttribution=)]
    2010-09-21 guoyibin

    #安慰剂对照#

    0

相关资讯

2009版乳腺癌NCCN指南(中文版)

2009_乳腺癌_NCCN_指南中文版.pdf